Leeds Teaching Hospitals collaborates on AI cancer test

A large-scale retrospective study carried out in Leeds, found that as many as one in five referrals into the two-week wait pathway could be safely ruled out using the Pinpoint test. The study concluded the test was affordable and could be deployed rapidly to any NHS pathology laboratory with no additional hardware requirements. The current evaluation in Leeds will see if the Pinpoint matches or exceeds the success of the retrospective study. If results are successful, it could then be rolled out across the nine major cancer pathways: breast, gynaecological, hematological, head and neck, lower gastrointestinal, lung, skin, upper gastrointestinal and urological. The Pinpoint test has already received more than £1.7m in grants from SBRI Healthcare and the national NHS Cancer Programme to help support a wider rollout.